The following full text is a publisher's version.

For additional information about this publication click this link.
https://hdl.handle.net/2066/215686

Please be advised that this information was generated on 2020-11-07 and may be subject to change.
Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile

Rosa De Groot, Marleen M. Van Loenen, Aurélie Guislain, Benoît P. Nicolet, Julian J. Freen-Van Heeren, Onno J.H.M. Verhagen, Michel M. Van Den Heuvel, Jeroen De Jong, Patrick Burger, C. Ellen Van Der Schoot, Robbert M. Spaapen, Derk Amsen, John B. A. G. Haanen, Kim Monkhorst, Koen J. Hartemink & Monika C. Wolkers

To cite this article: Rosa De Groot, Marleen M. Van Loenen, Aurélie Guislain, Benoît P. Nicolet, Julian J. Freen-Van Heeren, Onno J.H.M. Verhagen, Michel M. Van Den Heuvel, Jeroen De Jong, Patrick Burger, C. Ellen Van Der Schoot, Robbert M. Spaapen, Derk Amsen, John B. A. G. Haanen, Kim Monkhorst, Koen J. Hartemink & Monika C. Wolkers (2019) Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile, OncoImmunology, 8:11, e1648170, DOI: 10.1080/2162402X.2019.1648170

To link to this article: https://doi.org/10.1080/2162402X.2019.1648170

© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC

Published online: 15 Aug 2019.

Article views: 1385

View supplementary material

Submit your article to this journal

View related articles

View Crossmark data
Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile

Rosa De Groot, Marleen M. Van Loenen, Aurélie Guislain, Benoit P. Nicolet, Julian J. Freen, Van Heeren, Onno J.H.M. Verhagen, Michel M. Van Den Heuvel, Jeroen De Jong, Patrick Burger, C. Ellen Van Der Schoot, Robert M. Spaapen, Derk Amsen, John B. A. G. Haanen, Kim Monkhorst, Koen J. Hartemink, and Monika C. Wolkers

Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands; Oncide Institute, Utrecht, Netherlands; Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; Department of Immunohematology, Sanquin Research, Amsterdam, The Netherlands; Department of Pathology, (NKI-AvL), Amsterdam, The Netherlands; Laboratory of Cell Therapy, Sanquin Research, Amsterdam, The Netherlands; Department of Immunopathology, (NKI-AvL), Amsterdam, The Netherlands; Department of Surgery, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AvL), Amsterdam, The Netherlands

ABSTRACT
Non-small cell lung cancer (NSCLC) is the second most prevalent type of cancer. With the current treatment regimen, the mortality rate remains high. Therefore, better therapeutic approaches are necessary. NSCLCs generally possess many genetic mutations and are well infiltrated by T cells (TIL), making TIL therapy an attractive option. Here we show that T cells from treatment naive, stage I-IIa NSCLC tumors can effectively be isolated and expanded, with similar efficiency as from normal lung tissue. Importantly, 76% (13/17) of tested TIL products isolated from NSCLC lesions exhibited clear reactivity against primary tumor digests, with 0.5%-30% of T cells producing the inflammatory cytokine Interferon (IFN)-γ. Both CD4+ and CD8+ T cells displayed tumor reactivity. The cytokine production correlated well with CD137 and CD40L expression. Furthermore, almost half (7/17) of the TIL products contained polyfunctional T cells that produced Tumor Necrosis Factor (TNF)-α and/or IL-2 in addition to IFN-γ, a hallmark of effective immune responses. Tumor-reactivity in the TIL products correlated with high percentages of CD103+CD69+CD8+ T cell infiltrates in the tumor lesions, with PD-1+CD4+ T cells, and with FoxP3+CD25+CD4+ regulatory T cell infiltrates, suggesting that the composition of T cell infiltrates may predict the level of tumor reactivity. In conclusion, the effective generation of tumor-reactive and polyfunctional TIL products implies that TIL therapy will be a successful treatment regimen for NSCLC patients.

KEYWORDS
Non-small cell lung cancer; tumor infiltrating T cells; tumor reactivity; cytokines; polyfunctional T cells

CONTACT
Monika Wolkers m.wolkers@sanquin.nl Sanquin Research Department of Hematopoiesis and Landsteiner Laboratory, Amsterdam UMC.

ARTICLE HISTORY
Received 3 June 2019
Revised 9 July 2019
Accepted 23 July 2019

INTRODUCTION
Non-small cell lung cancer (NSCLC) is one of the most prevalent types of cancer worldwide. With the current treatment regimens, the 5-year survival rate of patients suffering from NSCLC is still limited. Because of the striking effects of immunotherapy in melanoma, recent efforts are directed towards treatment with immunotherapy for NSCLC patients. NSCLC are considered immunogenic, because they often contain high numbers of somatic mutations which is induced by smoking tobacco. Furthermore, they are well infiltrated by T cells. The functionality of these tumor infiltrated T lymphocytes (TILs) has, however, not been well documented. Treatment with anti-PD-1 is currently standard of care for stage IV NSCLC patients with distant metastasis. This therapy resulted in tumor regression in 17–30% of the patients. The majority of patients with NSCLC thus does not benefit from immune checkpoint blockade. Tumors in these patients utilize different immunosuppressive pathways that need to be overcome in order for immunotherapy to work. Therefore, additional immunotherapy interventions should be explored for the treatment of NSCLC patients, possibly in combination with the existing anti-PD-1 therapy.

One therapeutic opportunity for intervention is the infusion of TILs. Adoptive transfer of ex vivo expanded TILs has proven highly effective for stage IV melanoma patients, with impressive 50% overall response rates in pretreated patients. Of these melanoma patients, 10–20% experience durable complete remission. Tumor-reactive T cells were already detected in the mid 1990s in NSCLC lesions, and a clinical effect of TIL therapy for stage IV NSCLC patients has been reported, albeit with very minor improvements in survival. Since that time, the treatment regimen substantially improved, by speeding up the protocols to culture and expand TILs from tumor lesions, and by pre-conditioning the patient with non-myeloablative chemotherapy that allowed for the above-mentioned success rates in melanoma patients.

CONTACT
Monika Wolkers m.wolkers@sanquin.nl Sanquin Research Department of Hematopoiesis and Landsteiner Laboratory, Amsterdam UMC.

ARTICLE HISTORY
Received 3 June 2019
Revised 9 July 2019
Accepted 23 July 2019

INTRODUCTION
Non-small cell lung cancer (NSCLC) is one of the most prevalent types of cancer worldwide. With the current treatment regimens, the 5-year survival rate of patients suffering from NSCLC is still limited. Because of the striking effects of immunotherapy in melanoma, recent efforts are directed towards treatment with immunotherapy for NSCLC patients. NSCLC are considered immunogenic, because they often contain high numbers of somatic mutations which is induced by smoking tobacco. Furthermore, they are well infiltrated by T cells. The functionality of these tumor infiltrated T lymphocytes (TILs) has, however, not been well documented. Treatment with anti-PD-1 is currently standard of care for stage IV NSCLC patients with distant metastasis. This therapy resulted in tumor regression in 17–30% of the patients. The majority of patients with NSCLC thus does not benefit from immune checkpoint blockade. Tumors in these patients utilize different immunosuppressive pathways that need to be overcome in order for immunotherapy to work. Therefore, additional immunotherapy interventions should be explored for the treatment of NSCLC patients, possibly in combination with the existing anti-PD-1 therapy.

One therapeutic opportunity for intervention is the infusion of TILs. Adoptive transfer of ex vivo expanded TILs has proven highly effective for stage IV melanoma patients, with impressive 50% overall response rates in pretreated patients. Of these melanoma patients, 10–20% experience durable complete remission. Tumor-reactive T cells were already detected in the mid 1990s in NSCLC lesions, and a clinical effect of TIL therapy for stage IV NSCLC patients has been reported, albeit with very minor improvements in survival. Since that time, the treatment regimen substantially improved, by speeding up the protocols to culture and expand TILs from tumor lesions, and by pre-conditioning the patient with non-myeloablative chemotherapy that allowed for the above-mentioned success rates in melanoma patients.

CONTACT
Monika Wolkers m.wolkers@sanquin.nl Sanquin Research Department of Hematopoiesis and Landsteiner Laboratory, Amsterdam UMC.

ARTICLE HISTORY
Received 3 June 2019
Revised 9 July 2019
Accepted 23 July 2019

INTRODUCTION
Non-small cell lung cancer (NSCLC) is one of the most prevalent types of cancer worldwide. With the current treatment regimens, the 5-year survival rate of patients suffering from NSCLC is still limited. Because of the striking effects of immunotherapy in melanoma, recent efforts are directed towards treatment with immunotherapy for NSCLC patients. NSCLC are considered immunogenic, because they often contain high numbers of somatic mutations which is induced by smoking tobacco. Furthermore, they are well infiltrated by T cells. The functionality of these tumor infiltrated T lymphocytes (TILs) has, however, not been well documented. Treatment with anti-PD-1 is currently standard of care for stage IV NSCLC patients with distant metastasis. This therapy resulted in tumor regression in 17–30% of the patients. The majority of patients with NSCLC thus does not benefit from immune checkpoint blockade. Tumors in these patients utilize different immunosuppressive pathways that need to be overcome in order for immunotherapy to work. Therefore, additional immunotherapy interventions should be explored for the treatment of NSCLC patients, possibly in combination with the existing anti-PD-1 therapy.

One therapeutic opportunity for intervention is the infusion of TILs. Adoptive transfer of ex vivo expanded TILs has proven highly effective for stage IV melanoma patients, with impressive 50% overall response rates in pretreated patients. Of these melanoma patients, 10–20% experience durable complete remission. Tumor-reactive T cells were already detected in the mid 1990s in NSCLC lesions, and a clinical effect of TIL therapy for stage IV NSCLC patients has been reported, albeit with very minor improvements in survival. Since that time, the treatment regimen substantially improved, by speeding up the protocols to culture and expand TILs from tumor lesions, and by pre-conditioning the patient with non-myeloablative chemotherapy that allowed for the above-mentioned success rates in melanoma patients.
Therefore, the efficacy to grow tumor-reactive TIL products from NSCLC lesions should be re-assessed, both in terms of cell expansion and the presence of cytokine-producing TILs in response to tumors. Furthermore, it is yet to be determined whether a specific T cell profile in tumor lesions correlates with the level of tumor reactivity of expanded TIL products.

Here, we show that most TIL products contain tumor-reactive T cells. In particular TIL products with high tumour reactivity are polyfunctional. Furthermore, tumour reactivity of the expanded TIL product correlated with the composition of the T cell compartment in the tumor lesions. We conclude that the generation of NSCLC-specific TIL products for therapeutic purposes is feasible and should be reconsidered for clinical application.

Materials and methods

Patient cohort and study design

Between June 2015 and June 2017, 25 treatment-naïve NSCLC patients were included in this study. Samples from 2 patients were excluded because of logistic issues. Table 1 depicts the patient characteristics of the remaining 23 donors. The cohort consisted of 10 male and 13 female donors between the age of 38 and 79 years (average 66.1 years) with clinical stage Ia-Va according to the TNM7 staging system for NSCLC, based on tumor size, nodal involvement and level of metastasis. All but two patients had a history of smoking.

The study protocol was designed to define the phenotype of TILs isolated from treatment naïve NSCLC compared to non-tumorous lung tissue (N = 16), to explore the capacity to expand TILs (N = 17) and to measure the presence of tumor-reactive T cells within TIL cultures (N = 17). The study was performed according to the Declaration of Helsinki (seventh revision, 2013), and executed with consent of the Institutional Review Board of the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, the Netherlands. Donor tissues were obtained directly after surgery, transported at room temperature in RPMI medium 1640 (Gibco) containing 50 ug/ml gentamycin (Sigma-Aldrich), 12,5 ug/ml Fungizone (Amphotericin B, Gibco) and 20% fetal bovine serum (FBS) (Bodego), weighed and processed within four hours. Distal healthy lung tissue as defined by the pathologist was taken as far away as possible from the tumor lesion.

Tumor stage and differentiation, and weight of the obtained tissues for this study are shown in Table 2. Tumor size ranged from T1a-T4 according to the TNM7 system, and specified as adenocarcinoma (AC, n = 14), squamous carcinoma (SCC, n = 5) and as NSCLC not otherwise specified (NOS, n = 4). On average 1420 mg tumor tissue was obtained, ranging from 23-9590 mg (Table 2).

Tissue digestion

The first five donors were used to optimize the digestion protocol for the highest yield of live CD45+ cells in single cell digests. Briefly, freshly isolated tumorous and non-tumorous lung tissue were finely chopped, and incubated for 45 min shaking at 37°C in IMDM (Gibco) containing 30 IU/ml collagenase IV (Worthington), 12,5 ug/ml Fungizone (Amphotericin B, Gibico) and 1% FBS. The digest was pelleted at 360 g for 10 min, and

Table 1. Patient characteristics.

| Donor | Clinical stage (TNM7*) | Gender | Age at surgery (Years) | Smoking history (Cigarettes/day) |
|-------|------------------------|--------|------------------------|---------------------------------|
| 1     | IIA                    | M      | 71                     | no (never)                      |
| 2     | IIA                    | M      | 53                     | yes (15/d)                      |
| 3     | IIb                    | M      | 77                     | yes (3/d)                       |
| 4     | 0-Ia1                  | F      | 67                     | yes (8/d)                       |
| 5     | IIb                    | F      | 57                     | yes (10/d)                      |
| 6     | IA1                    | F      | 59                     | yes (3/d)                       |
| 7     | IA1                    | F      | 61                     | yes (15/d)                      |
| 8     | IVA                    | M      | 64                     | yes (25/d)                      |
| 9     | IIA                    | M      | 60                     | yes (20/d)                      |
| 10    | IIb                    | M      | 56                     | yes (30/d)                      |
| 11    | IB                     | M      | 59                     | yes (20/d)                      |
| 12    | IIb                    | F      | 70                     | yes (20/d)                      |
| 13    | IA1                    | F      | 58                     | yes (8/d)                       |
| 14    | IA2                    | F      | 38                     | yes (20/d)                      |
| 15    | IA2                    | F      | 81                     | no (never)                      |
| 16    | IIb                    | F      | 63                     | yes (20/d)                      |
| 17    | IB                     | F      | 69                     | yes (10/d)                      |
| 18    | IB                     | F      | 56                     | yes (6/d)                       |
| 19    | IB                     | F      | 79                     | yes (5/d)                       |
| 20    | IIa1                   | M      | 73                     | yes (30/d)                      |
| 21    | IA3                    | F      | 51                     | yes (8/d)                       |
| 22    | IIb                    | M      | 61                     | yes (15/d)                      |
| 23    | excluded               |        |                        |                                 |
| 24    | excluded               |        |                        |                                 |
| 25    | IA3                    | M      | 69                     | yes (20/d)                      |

*American Joint committee on Cancer: Lung Cancer Staging, 7th edition, 2009
**PDL-1 Immune Cell score 0–4
TC = Tumor Cells; IC = Immune Cells; NA = Not Assessed

*Male; F = Female; d = day

Table 2. Tumor characteristics.

| Tumor | Pathology stage (TNM7*) | Tumor differentiation (%) | PDL-1 TC (IC0-4**) | Biopsy weight (mg) |
|-------|-------------------------|---------------------------|--------------------|-------------------|
| 1     | T2bN0M0 Adeno           | 0                         | IC1 1780           |
| 2     | T2bN0M0 Squamous        | 30                        | IC2 1075           |
| 3     | T2a N1M0 NSCLC NOS      | 40                        | IC1 89             |
| 4     | T0-a1N0M0 NSCLC NOS     | NA                        | NA 120             |
| 5     | T2bN1M0 NSCLC NOS       | 90                        | IC2 560            |
| 6     | T1aN0M0 NSCLC NOS       | 60                        | IC3 550            |
| 7     | T2bN0M0 Adeno           | 0                         | IC0 1960           |
| 8     | T2aN2M1a Squamous       | 0                         | IC0 1640           |
| 9     | T2bN0M0 Adeno           | 0                         | IC3 23             |
| 10    | T1aN1M0 Adeno           | 0                         | IC3 182            |
| 11    | T2bN0M0 Adeno           | 95                        | IC2 800            |
| 12    | T2bN1M0 Adeno           | 0                         | IC1 1460           |
| 13    | T1aN0M0 Adeno           | 30                        | IC2 268            |
| 14    | T1bN0M0 Adeno           | 2                         | IC1 221            |
| 15    | T1bN0M0 Adeno           | 0                         | IC0 570            |
| 16    | T2N1M0 Squamous         | 90                        | IC2 5770           |
| 17    | T2aN0M0 Squamous        | 90                        | IC2 600            |
| 18    | T2bN0M0 Adeno           | 1                         | IC2 2550           |
| 19    | T2aN0M0 Squamous        | 0                         | IC2 2550           |
| 20    | T4N0M0 Adeno            | 0                         | IC1 9590           |
| 21    | T1cN0M0 Adeno           | 90                        | IC2 600            |
| 22    | T3N2M0 Adeno            | NA                        | NA 1850            |
| 23    | excluded                | -                         | -                  |
| 24    | excluded                | -                         | -                  |
| 25    | T1cN0M0 Adeno           | 0                         | IC3 290            |
live cells were used for TIL. Per-CP-Cy5.5, anti-CD3 PerCP-Cy5.5, anti-CD279 FITC, anti-CD56 BV605, anti-CD27 BV510, anti-CD127 BV421, anti-CD103 PE-Cy7 and anti-CD25 PE (all from BD Biosciences). Alternatively, cells were stained for anti-Lag3 PE (BD Biosciences), and anti-TIGIT Alexa 647 (BD Biosciences). Live/dead fixable near IR APC-Cy7 (Invitrogen) was included for dead cell exclusion. Cells were washed twice with FACS buffer and fixed for 30 minutes with the Perm/Fix Foxp3 staining kit (Invitrogen) according to the manufacturer’s protocol using anti-Foxp3 Alexa647 (Biolegend). Cells were resuspended in FACS buffer and passed through a 70 µm single cell filter prior to flow cytometry analysis (LSR fortessa, BD biosciences). The first six donors were used to optimize the staining panel and cytometry settings, by antibody titration and the use of single stains in combination with the minus one fluorochrome method (MOF).

T cells from pre-REP or REP cultures were stained prior to T cell activation with anti-CD4 BUV496, anti-CD8 BUV805 as described above. After the full activation protocol, cells were washed twice with FACS buffer and stained with anti-CD154 BV510 and anti-CD279 BV421 (Biolegend) and Live/dead fixable near IR APC-Cy7 in FACS buffer for 30 minutes at 4°C, and washed twice in PBS. Cells were then fixed and stained with anti-CD137 PE-Cy7, anti-IFN-γ PE, anti-TNF-α Alexa488 and anti-IL-2 APC (Biolegend) with the Cytofix/CytoPerm staining kit (BD Biosciences) according to the manufacturer’s protocol. Anti-CD107 Alexa700 (BD Biosciences) was included during the co-culture with tumor cells. Cells were washed in FACS buffer and passed through a 70 µm single cell filter prior to acquisition with the LSR fortessa (BD). Flow cytometry settings were defined for each patient material using single stainings for each antibody. To each flow cytometry analysis of patient material, a standardized sample of PBMCs pooled from ten healthy donors that was cryo preserved prior to the start of the study was included. Data analysis was performed with Flowjow Star 10.1.

Immunohistochemistry on tumor tissue
PD-L1 expression on formalin-fixed, paraffin-embedded tissue samples was assessed with immunohistochemistry using the monoclonal antibody 22C3 from Agilent on a Ventana Benchmark Ultra. At least 100 neoplastic cells were scored for membranous staining. Tumor cell PD-L1 scores were described as percentages of total tumor cells. ICs are scored as the proportion of tumor area that is occupied by PD-L1 staining of immune cells of any intensity and categorized in IC0-4 representing the following cutoffs: 0%, 0–5%, 5–10% and >10%.

Clonal T cell analysis
For clonal T cell analysis, CD3^+ CD8^+ T cells and CD3^+ CD4^+ T cells (excluding CD25^hi CD127^− T cells to exclude Tregs) from tumor digests and from the corresponding REP TIL were FACS-sorted. Cells were washed with PBS, and cell pellets snapfrozen in liquid nitrogen were stored at −30°C. DNA extraction was performed with NucleoSpin Tissue XS (Macherey Nagel) according to the manufacturer’s instructions. Complete TCR beta rearrangements were amplified in multiplex PCR with sets of Vbeta- and J beta-specific primers, respectively. In a nested PCR (20 cyclci) barcodes and the Ion Torrent specific adaptors A en P1 were added to the PCR products. The DNA library was sequenced on the Ion S5 sequencer according to manufacturer’s instruction. Files containing the Unprocessed sequencing reads (fastq) were analysed with mixcr version 3.0.521 using “TCR output only” option. Txt output was then imported in R (3.5.1) resuspended in FACS buffer (PBS containing 2% FBS and 2 mM EDTA). Digest was filtered first through a tea mesh and then over a 100 um filter. After red blood cell lysis for 15 min at 4°C with 155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA (pH 7.4), live and dead cells were manually counted with trypan blue solution (Sigma) on the hemocytometer. From six donors, the tumor tissue was divided in three regions. A sample from each region was separately processed for TIL culture. The remaining tissue was combined for the total tumor digest. After digestion, 1–2 × 10^6 live cells were used for flow cytometry analysis, and 1–3 × 10^6 live cells were used for TIL cultures. The remaining digest was cryo-preserved until further use.

**T cell expansion**
TIL cultures and T cell cultures from distal lung tissue digests were performed as previously described for melanoma-derived TILs. Briefly, 2–3 wells containing 0,5–1×10^6 live cells from the tissue digest were cultured for 10–13 days in 24 wells plates in 20/80 T-cell mixed media (Miltenyi) containing 5% human serum (HS) (Sanquin), 5% FBS, 50 µg/ml gentamycin, 1,25 µg/ml fungizone, and 6000 IU human recombinant (hr) IL-2 (Proleukin, Novartis) (pre-Rapid Expansion Phase; pre-REP). Media was refreshed on days 7, 9 and 11. Wells were split when a monolayer of cells was observed in the entire well. When more than 30% of the cells stopped dividing (determined as rounding up of cells), cells were harvested, counted and prepared for an additional culture period of 10–13 days (REP). 2 × 10^5 live cells/well (1–3 wells/donor) were co-cultured with 5–10 × 10^6 irradiated PBMCs pooled from 10 healthy donors in 24 wells, 30 ng/ml anti-CD3 antibody (OKT-3) (Miltenyi Biotec) and 3000 IU/ml human IL-2. Typically, cells were passedaged at day 5, 7, 9 and 11 and harvested, washed and counted on day 10–13, based on visual assessment of the T cell proliferation stage as above. Cells were either tested immediately for reactivity, or cryo-preserved in IMDM containing 10% DMSO (Corning) and 30% FBS until further use.

**T cell activation**
After thawing and live cell counting as described above, pre-REP and REP T cells were pre-stained in FACS buffer with anti-CD4 BUV496, anti-CD8 BUV805 (BD Biosciences) for 30 min at 4°C. Cells were washed twice, one time in FACS buffer and then in 20/80 T-cell mixed media (Miltenyi). 100.000 live T cells were co-cultured with 200.000 live tumor digest cells or normal lung digest cells for 6 h at 37°C, were stimulated with 10 ng/ml PMA and 1 µg/ml PMA and 1 μg/ml Ionomycin (SigmaAldrich), and with anti-CD8 BUV805, anti-CD45RA BUV496, and anti-CD69 BUV395 (from BD Biosciences). Alternatively, cells were stained for anti-Lag3 PE (BD Biosciences), and anti-TIGIT Alexa 647 (BD Biosciences). Live/dead fixable near IR APC-Cy7 (Invitrogen) was included for dead cell exclusion. Cells were washed twice with FACS buffer and fixed for 30 minutes with the Perm/Fix Foxp3 staining kit (Invitrogen) according to the manufacturer’s protocol using anti-Foxp3 Alexa647 (Biolegend). Cells were resuspended in FACS buffer and passed through a 70 µm single cell filter prior to flow cytometry analysis (LSR fortessa, BD biosciences). The first six donors were used to optimize the staining panel and cytometry settings, by antibody titration and the use of single stains in combination with the minus one fluorochrome method (MOF).

T cells from pre-REP or REP cultures were stained prior to T cell activation with anti-CD4 BUV496, anti-CD8 BUV805 as described above. After the full activation protocol, cells were washed twice with FACS buffer and stained with anti-CD154 BV510 and anti-CD279 BV421 (Biolegend) and Live/dead fixable near IR APC-Cy7 in FACS buffer for 30 minutes at 4°C, and washed twice in PBS. Cells were then fixed and stained with anti-CD137 PE-Cy7, anti-IFN-γ PE, anti-TNF-α Alexa488 and anti-IL-2 APC (Biolegend) with the Cytofix/CytoPerm staining kit (BD Biosciences) according to the manufacturer’s protocol. Anti-CD107 Alexa700 (BD Biosciences) was included during the co-culture with tumor cells. Cells were washed in FACS buffer and passed through a 70 µm single cell filter prior to acquisition with the LSR fortessa (BD). Flow cytometry settings were defined for each patient material using single stainings for each antibody. To each flow cytometry analysis of patient material, a standardized sample of PBMCs pooled from ten healthy donors that was cryo preserved prior to the start of the study was included. Data analysis was performed with Flowjow Star 10.1.

**Clonal T cell analysis**
For clonal T cell analysis, CD3^+ CD8^+ T cells and CD3^+ CD4^+ T cells (excluding CD25^hi CD127^− T cells to exclude Tregs) from tumor digests and from the corresponding REP TIL were FACS-sorted. Cells were washed with PBS, and cell pellets snapfrozen in liquid nitrogen were stored at −30°C. DNA extraction was performed with NucleoSpin Tissue XS (Macherey Nagel) according to the manufacturer’s instructions. Complete TCR beta rearrangements were amplified in multiplex PCR with sets of Vbeta- and J beta-specific primers, respectively. In a nested PCR (20 cyclci) barcodes and the Ion Torrent specific adaptors A en P1 were added to the PCR products. The DNA library was sequenced on the Ion S5 sequencer according to manufacturer’s instruction. Files containing the Unprocessed sequencing reads (fastq) were analysed with mixcr version 3.0.521 using “TCR output only” option. Txt output was then imported in R (3.5.1)
under R Studio (1.1.433) and further analyzed using tcR version 2.2.3.22 Clone frequency and shared repertoire analysis on nucleic-acid sequences was analyzed with tcR. CD4 and CD8 clones in each donors were filtered using tcR and plotted in bar graphs made in R using ggplot 2 version 3.0.0.

Statistical analysis
Statistical analyses were performed with Graphpad Prism 7.2. Compiled data are shown as paired data points for each patient, or as single data points with box and whiskers showing maximum, 75th percentile, median, 25th percentile, minimum and mean, unless otherwise indicated in the legend.

Overall significance of differences were calculated with repeated measurement paired one-way ANOVA test with Tukey's post hoc test comparing columns. If differences were confirmed ($p < 0.05$), significance between two data points was calculated using paired Student's $t$ test, with the $p$ value cut-off of $*$ = $p < 0.05$; ** = $p < 0.01$; and *** = $p < 0.001$. If Student's $t$ test showed $p$ values $>0.05$, $p$ value marking was omitted in panels. Correlations were calculated using Pearson’s correlation in combination with linear regression.

Results

High yield of lymphoid cells isolated from NSCLC tumor lesions
We first determined the efficiency of isolating TILs from NSCLC lesions that underwent lobectomy. 23 patients from treatment-naive stage Ib-IVa NSCLC patients suffering from non-squamous (n = 14), squamous (n = 5), or from NSCLC not otherwise specified (n = 4) were included in this study (Table 1).

To evaluate the TIL isolation and expansion procedure from the tumor, we also isolated normal lung tissue from the same patients that was harvested as far away as possible from the tumor lesion.

To determine if sufficient cell numbers could be obtained from NSCLC tumor lesions for TIL expansion, we enumerated the overall cell numbers of tumor digests, and the number of T cell infiltrates. From the tumor digests, we obtained on average $33.6 \times 10^3$ viable cells/mg tissue, which was comparable to the yield from normal lung tissue digests, with on average $51.2 \times 10^3$ viable cells/mg tissue (Figure 1(a)). In line with previous studies,7,8,23 high numbers of CD3+CD56− T cells cells were detected not only in tumor tissue, but also in normal lung tissue, with $23.7 \pm 16.9\%$ and $15.5 \pm 13.1\%$ of live cells in the respective tissue digests (Figure 1(b)). The percentage of CD3+CD56− T cells within the live cell population was significantly increased in most tumor infiltrates (Figure 1(c,d)). Live cell counts/mg tissue and T cell percentages thereof, together translated into an average $17.8 \times 10^3$ T cells/mg lung tissue and $9.8 \times 10^3$ T cells/mg tumor tissue (Figure 1(c,d)). Of note, sufficient cell numbers for TIL expansion and phenotypic analysis could be isolated from all donors, even from tumors of <1 cm$^3$.

Effective TIL expansion from NSCLC tumors
The expansion efficiency of TILs highly depends on the tumor type and the culture protocol.1,12 We here determined the efficiency of TIL expansion from 17 tumor digests with the rapid expansion protocol (REP) established for melanoma TILs.1,2 For comparison, we included 9 normal lung tissue digests. Tumor and lung tissue digests were cultured for 10–13 days in the presence of IL-2 (pre-REP), followed by a 10–13 day restimulation with the α-CD3 antibody OKT-3 and IL-2 (REP). During pre-REP, CD3+ T cells from tumor and lung digest expanded on average 4- and 6-fold, respectively (Figure 1(e)). REP cultures expanded CD3+ T cells from the tumor 470-fold and from the lung 570-fold, resulting in an overall expansion of on average 2000-fold for tumor TILs, with a minimum of 540-fold, and 3000-fold lung tissue derived T cells (Figure 1(e)). In conclusion, T cells from normal lung tissue may expand slightly better, probably because the immunosuppressive cues from the tumorous tissue during T cell culture, are lacking. Nevertheless, the overall efficiency of expanding NSCLC-derived T cells was comparable to the recently reported expansions of therapeutically employed melanoma-derived TILs,1,2 and would thus be compatible for clinical use.

We then measured the percentages of CD4+ and CD8+ T cells in the pre-REP and REP cultures from tumor digests. CD4+ T cells increased from $14.3 \pm 9.6\%$ ex vivo of total live cells to $43.3 \pm 26.5\%$ after REP, and CD8+ T cells increased from $10.3 \pm 8.3\%$ to $53.4 \pm 27.0\%$ (Figure 1(f)). CD8+ T cells expanded generally better than CD4+ T cells in these culture conditions, as revealed by the changes over time in the CD8+/CD4+ T cell ratio (Figure 1(g)). The rate of T cell expansion did not correlate with the PD-L1 expression on tumor cells or immune infiltrates, or with the T cell differentiation status (naive/effector/memory) within the tumor tissue (Supplemental Figure 1).

We next investigated the phenotypic alterations in T cell composition of the expanded TIL products. TIL expansion resulted in a drop of FOXP3-expressing CD4+ to <0.1% of the CD4 T cells (Supplemental Figure 2A). Furthermore, even though LAG-3 and TIGIT expression increased upon T cell cultures, the expression of PD-1 expression substantially diminished upon T cell expansion (Supplemental Figure 2B). We also interrogated whether and how the T cell clonality altered upon T cell expansion. CDR3 nucleic acid sequence analysis of the TCRβ chain revealed that both CD4+ and CD8+ T cells are in general polyclonal in NSCLC tumor lesions, and that this polyclonality is maintained upon expansion (Figure 1(h)). Furthermore, tumor-derived and expanded CD4+ and CD8+ T cells showed overlapping T cell clones, a feature that was more pronounced in CD8+ T cells (Figure 1(h), Supplemental Figure 3). In conclusion, both CD4+ and CD8+ T cells from NSCLC expanded well with the REP culture conditions, and maintained their polyclonal profile.

The majority of TIL products contain tumor-specific T cells
We next examined the tumor reactivity of expanded TILs. As a read-out, we measured the production of the pro-inflammatory cytokine IFN-γ by expanded TILs upon co-culture with autologous tumor digest. This production was compared to co-culture with normal lung tissue digest, or with medium alone. To
distinguish the expanded TILs from the high T cell infiltrates within the tissue digests, we pre-stained the expanded TILs with CD4 and CD8 antibodies prior to co-culture.

IFN-γ producing T cells in response to tumor tissue were detected in 16/17 tumor digests (Figure 2(a,b)). On average, 6.3 ± 7.8% of the T cells from the TIL products produced IFN-γ when co-cultured with tumor digests (Figure 2(a,b)). We detected similar percentages of IFN-γ-producing T cells within the total CD4⁺ and CD8⁺ T cell population, with 5.8 ± 6.3% and 6.5 ± 9.4% of each population, respectively (Figure 2(a,b)).

Interestingly, we detected 2.3 ± 2.9% IFN-γ-producing T cells in the TIL products upon co-culture with lung digests, which was...
Figure 2. Most NSCLC-derived TIL products contain tumor-reactive T cells. (a, b) REP TILs were pre-stained with CD4 and CD8 antibodies, and cultured for 6 hours in the presence of brefeldin A with medium alone, with digests from normal lung tissue, or with autologous tumor digest. (a) Representative dot plots, and (b) compiled data of TIL products derived from 17 donors (top), and of T cells expanded from non-tumorous lung tissue from 11 donors (bottom). The percentage of IFN-γ producing CD3+ T cells (left panel), by CD4+ T cells (middle panel) and by CD8+ T cells (right panel) is depicted as determined by flow cytometry. Each dot represents one donor, box and whisker plots depict the median (line), minimum and maximum values (whiskers) and 25th and 75th pct (box). (c) TILs of 6 donors were expanded from the total digest, or from three distinct regions of the tumor lesion (region A, B, C). IFN-γ production of the different TIL products was compared after 6h of culture with the total tumor digest. (d) IFN-γ production by CD4+ and CD8+ T cells upon activation with PMA-Ionomycin. [Paired student’s T test; * p < .05; ** p < .01; *** p < .001. If no indication, p ≥ 0.05].
higher than those of TILs cultured with medium alone (1.1 ± 1.0%; Figure 2(a,b)). The reactivity could be due to undetected tumor cell dissemination, distal tumor antigen presentation by dendritic cells, or bystander T cells that are not tumor-specific and thus may also respond to normal lung cells. The reactivity to normal lung tissue digests could also reflect innate immune responses by T cells that are triggered in a non-antigen specific manner. We only considered TIL products tumor-reactive when the percentage of IFN-γ producing T cells was higher in response to the tumor digest than that to the normal lung digest. 13/17 (76%) of the TIL products fulfilled this requirement (see also below). We also tested the cytokine production of T cells that were expanded from lung digests. Only 2 out of 11 T cell products produced IFN-γ upon exposure to normal lung tissue, and only one lung-derived T cell product produced IFN-γ upon co-culture with tumor digest (Figure 2(b)), indicating that the IFN-γ production from TILs is tumor-specific. Combined, these data indicate that tumor-reactive T cells are highly prevalent in expanded TIL products from NSCLC.

The percentage of T cells producing IFN-γ varied considerably between donors, ranging from 0.3% to 27.5% (Figure 2(b)). This variation in tumor-reactivity could result from high heterogeneity of NSCLC tumors and thus depend on the tumor region that was isolated for TIL expansion. However, we consider this possibility unlikely, because the percentage of IFN-γ+ T cells expanded from whole tumor lysates was comparable to that of TILs that were expanded from three distinct parts of the same tumor (Figure 2(c)). Furthermore, all TIL products produced substantial levels of IFN-γ in response to PMA/ionomycin stimulation (65.8 ± 16.4%; Figure 2(d)). There was no significant correlation between this potential to produce cytokines and the tumor-reactivity of TIL products (r = 0.11, p = .663). We therefore conclude that the majority of NSCLC-derived TIL products contain tumor-reactive T cells, but that the proportions thereof are variable.

**IFN-γ-producing tumor-reactive T cells express CD137 (4-1BB) and CD154 (CD40L)**

We next interrogated if measuring the production of IFN-γ alone was sufficient to reflect the actual tumor-reactivity of TIL products. We therefore included the analysis of markers that are rapidly induced upon T cell activation, such as the costimulatory molecules CD137 (4-1BB),27 and CD154 (CD40L).28 When expanded TILs were co-cultured for 6 h with tumor digest, we found a significant induction of CD137 expression in both CD4+ and CD8+ T cells (Figure 3(a,b), top panels). Furthermore, CD4+ T cells – but not CD8+ T cells – showed increased expression of CD154, a marker that was shown to identify antigen-specific CD4+ T cells in the peripheral blood28 (Figure 3(a,b), middle panels). CD279 (PD-1) expression instead was not induced in expanded TILs within the 6 h of co-culture with tumor digest (Figure 3(a,b), bottom panels), suggesting that the tumor-reactive T cells are not (immediately) susceptible to negative regulation by immunological checkpoints.

The majority of IFN-γ producing CD8+ T cells were CD137-positive (Figure 3(c,d)). Combining the expression of CD137 and CD154 with the production of IFN-γ in fact helped to accurately define the presence of tumor-reactive TILs, in particular when the percentage of IFN-γ production was low, and/or the background levels high. However, we also observed that IFN-γ-negative T cells can express CD137 and CD154 (Figure 3(e,f)), suggesting that the actual percentage of tumor-reactive T cells may be higher than estimated based on the production of IFN-γ.

**NSCLC-reactive TILs produce TNF-α and IL-2, and can be polyfunctional**

In addition to IFN-γ, other cytokines such as TNF-α and IL-2 play a critical role in effective T cell mediated immunity.29,30 This prompted us to determine whether TIL products from NSCLC produced these two cytokines. Interestingly, exposure to tumor digest resulted in significant induction of both TNF-α- and IL-2-producing T cells when compared to co-culture with lung digest or medium alone (Figure 4(a,b); Supplemental Figure 2A). This was observed for both CD8+ T cells, and for CD4+ T cells (Figure 4(a,b)).

To define the overall percentage of tumor-reactive TILs, we included all T cells that produced at least one of the three cytokines (Figure 4(b), left panel). We substracted the response of the TIL product against the tumor digest from the response against autologous distal lung tissue digest (Figure 4(b), left panel). This stringent cut-off revealed that in some tumor lesions (patient 7 and 14) the observed tumor responses were not higher than the response to the distal lung tissue (Figure 4(b)). We therefore considered the TIL product from these lesions as negative. Overall, again 13/17 TIL products (76.5%) showed higher cytokine production towards the tumor digest (Figure 4(b), left panel).

We next divided tumor-reactive TIL products into three categories. 4/17 (23.5%) expanded TILs did not produce cytokines above background levels. 8/17 (47.1%) TIL products contained up to 5% of cytokine-producing T cells (intermediate responder, Figure 4(b), left panel). Importantly, 5/17 (29.4%) TIL products contained at least 6%, and up to 31% cytokine-producing T cells above background levels (high responder; Figure 4(b), left panel). We also detected CD107 expression in the tested TIL products upon co-culture with tumor digest (Supplemental Figure 4). Furthermore, high responders contained TIL products from SCC (patient 8, 17 and 19) and from AC (patient 20 and 21). Also, all tumor stages were equally distributed in high, intermediate and non-responders. These findings thus reveal that TIL products from NSCLC can contain high levels of tumor-reactive T cells independent of tumor stage or differentiation status.

Polyfunctional T cells that produce more than one cytokine simultaneously are considered the most potent effector T cells against chronic infections.31,32 This is also observed for T cell responses against tumors.29,30 We therefore investigated whether NSCLC-derived TIL products contain these polyfunctional T cells. Strikingly, all high responders contained T cells that produced 2 or 3 cytokines (Figure 4(b), right panel). Of the 8 intermediate responders, patient 7 and 11 also contained polyfunctional T cells (Figure 4(b), right panel). Polyfunctional responses to tumor digests were observed for both CD4+ and CD8+ T cells (Figure 4(b), right panel). Single cytokine producers included all three cytokines (Figure 4(c), top panel). Likewise,
double cytokine producers could produce 2 out of the three cytokines in all possible combinations (Figure 4(c), top panel). Nevertheless, whereas intermediate responders (1–5% of total cytokine production; Figure 4(b)) were more skewed towards single cytokine producers, high responders contained single double and triple producers (Figure 4(c), bottom right panel).

Figure 3. IFN-γ producing TILs express CD137 and CD40L, but not PD-1. REP TILs were cultured for 6 hours in the presence of brefeldin A with medium alone, with digests from normal lung tissue or with autologous tumor digest. (a) Representative histograms of CD137 (4-1BB), CD154 (CD40L), and CD279 (PD-1) expression of CD8+ and CD4+ T cells (left panel) and CD8+ T cells within the IFN-γ+ T cells (right panel). Gates are set to isotype control. (c) Representative dot plots and (d) compiled data of percentage of T cells that co-express IFN-γ and CD137, CD154, or CD279 of CD4+ T cells (left panel) and CD8+ T cells (right panel). Gates are set to isotype control (C, left panels). (e) Representative histograms and (f) compiled data of the percentage of CD137, CD154, and CD279 – expressing CD4+ and CD8+ T cells within the IFN-γ producing (positive) and negative cells. Gates are set to isotype control. Each dot represents one donor, box and whisker plots depict minimum, 25th pct, median, 75th pct and maximum values. [Paired student’s T test; * p < .05; ** p < .01; *** p < .001. If no indication, p ≥ .05].
Figure 4. NSCLC-derived TIL products can be polyfunctional. (a) Percentage of TNF and IL-2 production of T cells (left panel), CD4+ T cells (middle panel) and CD8+ T cells (right panel) as determined by flow cytometry, n = 17 donors. Each dot represents one donor, box and whisker plots depict minimum, 25th, median, 75th, and maximum values. (b) Left panel: Percentage of cytokine-producing T cells that were cultured with tumor digest, minus the percentage of cytokine production of T cells stimulated with lung digest (n = 17). Right panel: Total percentage of cytokine producing T cells. The percentage of cytokine producing CD4+ T cells (dark colors) and CD8+ T cells (light colors) is depicted when exposed to tumor digest (top bar), or to the lung digest (bottom bar). Color coding indicates the production of 1 (blue) 2 (purple), or 3 (yellow) cytokines simultaneously. Each patient is indicated with a number. (c) Top: Relative contribution of cytokine production profile of high and intermediate responders depicted in panel B. non-responders were excluded from this analysis. Bottom left: Ratio of tumor reactive CD8+ over CD4+ T cells, in relation to the percentage of cytokine-producing T cells. Bottom right: relative contribution of single, double and triple cytokine producers in high responders (high R), and intermediate responders (Im R) as defined in panel B.
Interestingly, tumor-reactive T cells were also more equally distributed between CD4+ and CD8+ T cells in high responders (Figure 4(b), right panel), and the overall ratio of CD8+ T cells over CD4+ T cells in REP products of high responders was close to 1, whereas this ratio was not skewed to either T cell subset in intermediate and no responders (Figure 4(c), bottom left panel). In conclusion, most TIL products contained tumor-reactive CD4+ and CD8+ T cells, and in particular high responders comprised of polyfunctional T cells, indicative for potent antitumoral TIL products generated from NSCLC tumors.

**Tumor-specific alterations in T cell composition correlate with tumor-reactivity of TIL products**

We next investigated whether the high variation in tumor reactivity between TIL products related to specific features of T cells in the original tumor tissue. Because the composition of T cell infiltrates is highly variable between individuals (see below), we used the normal lung tissue as base line for each patient to define the tumor-specific T cell signature.

Tumor tissues showed a modest, but significant increase in CD8+ T cell infiltrates compared to lung tissue, a feature that was not observed for CD4+ T cells (Figure 5(a)). Tumor lesions contained in particular higher percentages of CD27+CD45RA+ central memory T cells (Supplemental Fig. 5), as well as FOXP3+CD25hi CD4+ T cells (Figure 5(b)). These FOXP3+CD4+ T cells did not express the IL-7 receptor alpha chain (CD127), identifying them as bona fide regulatory T cells (Figure 5(b)).

The percentages of CD8+ T cells that express both the integrin CD103 and the retention marker CD69 in the tumor lesion significantly exceeded those in normal lung, which were already high (Figure 5(c)). For CD4+ T cells, we instead observed a drop of CD69hi CD103+ expressing cells in the tumor when compared to the normal lung tissue (Figure 5(c)). As expected, we found that PD-1hi expressing CD4+ and CD8+ T cells were substantially increased in the tumor lesions compared to normal lung tissue (Figure 5(d)).

Thus, tumor tissues contain high levels of FOXP3+CD25hi regulatory CD4+ T cells, PD-1hi CD4+ and CD8+ T cells, and high levels of CD69hi CD103+ CD8+ T cells.

To date, it is not known whether a specific ex vivo tumor-specific T cell signature correlates with the level of tumor-reactivity detected in the TIL products. We therefore used our cohort of 17 patients to obtain first insights in such correlations. To account for the high variation between patients already in the healthy lung (Figure 5), we used the tumor-specific increase of T cell subpopulations for this comparison (delta percentage; Δ %). The tumor-specific infiltration by CD4+ or CD8+ T cells, or the effector/memory phenotype of both T cell subsets did not correlate with the percentage of cytokine producing TILs (Figure 6(a), Supplemental Figure 5). Also the expression levels of PD-L1 on tumor cells or on immune infiltrates did not indicate high tumor reactivity (Figure 6(b)). However, when examining specific T cell subsets, we found that the percentage of CD69hi CD103+ CD8+ T cells positively correlated with the level of tumor-reactivity of expanded TIL products (Figure 6(c)). For CD4+ T cells, a positive correlation with tumor-reactivity was found for the percentage of PD-1hi CD4+ T cells (Figure 6(d)). Intriguingly, even though regulatory T cells are associated with a poor prognosis for NSCLC patients,17,18 we found that the presence of tumor-specific FOXP3+CD25hi CD4+ T cell infiltrates correlated positively with cytokine production of expanded TILs (Figure...
6(e)). Combined, our data suggest that the tumor-specific signature of CD4+ and CD8+ T cells and a high number of Treg infiltrates is indicative for strong tumor reactivity in the expanded TIL products.

**Discussion**

Here we show that tumor-specific TILs can be effectively expanded from the majority of NSCLC patients. Importantly, we found that TIL products that contain high percentages of tumor-reactive T cells produce not only IFN-γ, but also TNF-α and/or IL-2. T cells producing more than one cytokine are considered highly potent \(^{29,30}\) and vaccination strategies strive to generate these polyfunctional T cell responses. \(^{34}\) We therefore hypothesize that infusion of TIL products containing polyfunctional T cells should be effective against NSCLC.

Recently, it was shown that tumor-reactive TILs could be expanded from 80% of tested melanoma patients that did not respond to anti-PD-1 treatment. \(^{35}\) 2 out of 12 patients that were subsequently treated with TIL therapy showed objective clinical effects. \(^{35}\) These findings thus indicate that melanoma patients who are refractory to anti-PD-1 can still benefit from TIL therapy, and therefore anti-PD-1 and TIL therapy are complementary immunotherapeutic strategies. This could also be the case for NSCLC patients that did not respond to anti-PD-1 treatment. \(^{9-13}\)

Intriguingly, most NSCLC TIL products contain both tumor-reactive CD8+ T cells and CD4+ T cells. The cytolytic function of CD8+ T cells to control and/or eradicate tumors is well established, and tumor-reactive CD8+ T cells were recently expanded by others from NSCLC tumor digests and from peripheral blood. \(^{23,36,37}\) In our study the majority of TIL products contained tumor-reactive CD8+ T cells.

Much less is known about tumor-reactive CD4+ T cells. Recently, neo-antigen specific CD4+ T cells were identified in the majority of tested melanoma lesions. \(^{38}\) Furthermore, two patients that suffered melanoma and metastatic cholangiocarcinoma received TIL therapy with tumor-reactive CD4+ T cells only, and both patients showed clear clinical benefits from this treatment. \(^{39,40}\) Thus, CD4+ T cells can substantially contribute to anti-tumoral responses. Whether this effect is indirect through promoting effective CD8+ T cell responses, or direct by cytotoxic CD8+ T cells as proposed in murine...
tumor models is yet to be defined. These findings combined strongly suggest that in addition to the CD8+ T cells, these tumor-reactive polyfunctional CD4+ T cells could be of value for TIL therapy.

The composition of the tumor-infiltrating T cell compartment correlates with patient survival. Our study now showed that a correlation also exists between this composition and the likelihood that cytokine-producing tumor-reactive T cells are present in expanded TIL products. In line with previous studies that showed that the presence of CD8+ T cells expressing CD103 and CD69 serves as a favorable prognostic marker for survival, we describe here that their presence in the tumor lesion also correlated with high percentages of cytokine-producing CD8+ T cells in the TIL products. This was however not the case for CD4+ T cells. Conversely, high PD-1 expression of CD4+ T cells correlated with the presence of tumor-reactive T cells in the TIL product, which could be a consequence of the high percentage of tumor-reactive CD4 T cells in high responders, or due to other yet to be determined parameters. As PD-L1 expression on tumors did not correlate with tumor-reactivity of TIL products, it is tempting to speculate that PD-L1 expression on other immune infiltrates could contribute to this correlation.

To our surprise, even though the presence of FOXP3+ T cells in tumors is associated with poor survival, we found the highest levels of tumor-reactivity in TIL products when the percentage of Tregs in the tumor lesion was also high. To our knowledge this correlation has not been observed previously, possibly because the comparison of immune infiltrates from tumorous and non-tumorous tissue is not regularly included in the analysis of tumor-reactivity upon TIL expansion. One possible explanation for this correlation is the chronic exposure of immune cells to tumor tissue, a setting where as a part of the regular feed-back loops of immune responses, Tregs are recruited to quench ongoing T cell responses against the tumor. Indeed, a high correlation with tumor-reactive CD8+ T cell infiltrates is observed in murine melanoma models. Irrespective of the mechanism(s) that contribute to the correlation of high Treg numbers with high percentages of tumor-reactive T cells, it is tempting to speculate that patients with high Treg numbers may profit most from TIL therapy. Furthermore, even though a validation cohort of our findings is warranted, we propose that the presence of CD69+CD103+ on CD8+ T cells, PD-1hi CD4+ T cells, and high levels of Tregs in the tumor lesions may help identify the patients that are most likely to benefit from TIL therapy.

In conclusion, we here demonstrate that most tumor-reactive TIL products generated from NSCLC tumor lesions contain tumor-reactive T cells. We therefore suggest that TIL therapy should be considered as treatment for NSCLC patients.

Acknowledgments
We thank the Flow cytometry facility from Sanquin Research, and the medical assistance staff from the NCI-Avl for technical help.

Availability of data and material
All data generated or analysed during this study are included in this published article [and its supplementary information files].

Competing interests
The authors declare no competing interests

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Ethics approval and consent to participate
The study was performed according to the Declaration of Helsinki (seventh revision, 2013), and executed with consent of the Institutional Review Board of the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-Avl), Amsterdam, the Netherlands (CFMPB317).

Funding
This research was supported by intramural funding of Sanquin (PPOC-14-46); Stichting Sanquin Bloedvoorziening [PPOC 14-46].

ORCID
Rosa De Groot http://orcid.org/0000-0003-4070-0848
Aurélie Guislain http://orcid.org/0000-0002-3999-6648
Benoit P. Nicolet http://orcid.org/0000-0002-6765-7729
Julian J. Freen-Van Heeren http://orcid.org/0000-0003-0506-2756
Michel M. Van Den Heuvel http://orcid.org/0000-0002-6372-2153
C. Ellen Van Der Schoot http://orcid.org/0000-0002-8065-3540
Robbert M. Spaapen http://orcid.org/0000-0002-1329-8606
Monika C. Wolkers http://orcid.org/0000-0003-3242-1363

References
1. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16:2646–2655. doi:10.1158/1078-0432.CCR-10-0613.
2. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Pfan GQ, Kammula US, Hughes MS, Citrin DE, et al. CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010;16:6122–6131. doi:10.1158/1078-0432.CCR-10-0613.
3. Hodi FS, Hwu W-J, Kefferd R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510–1517. doi:10.1200/JCO.2015.64.0391.
Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefferd R, Joshua AM, Patnaik A, Hwu W-J, Weber JS, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600–1609. doi:10.1001/jama.2016.1007.

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biank AN, Bignell GR, Bolli N, Borg A, Borresen-Dale A-L, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421.

Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, Vignaud J-M. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Clin Med. 2002;140:320–328.

Kargl J, Busch SE, Yang GHY, Kim K-H, Hanke ML, Metz HE, Hubbard JJ, Lee SM, Madtes DK, McIntosh MW, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017;8:14381. doi:10.1038/ncomms14381.

Lizardo PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, Dries R, Almonte C, Herter-Sprie GS, Santos A, et al. Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes. JCI Insight. 2016;1:e90014. doi:10.1172/JCI.insight.89014.

Gettering S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, et al. Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36:1675–1684. doi:10.1200/JCO.2017.77.0412.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–1639. doi:10.1056/NEJMoa1507643.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwala C, Cubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;373:2018–2028. doi:10.1056/NEJMoa1501824.

Brahmer JR, Rodriguez-Abrue D, Robinson AG, Hui R, Coszti T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-006): a multicentre, randomised, open-label phase 3 trial. Lancet Oncol. 2016;17:1117–1127. doi:10.1016/S1470-2045(16)30187-2.

Reck M, Rodriguez-Abrue D, Robinson AG, Hui R, Coszti T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–1833. doi:10.1056/NEJMoa1606774.

Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330. doi:10.1038/nature21349.

Rosenberg SA, Restifo NP. Realising the promise: adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6248):62–68. doi:10.1126/science.aaa4967.

Melioli G, Ratto G, Guastella M, Meta M, Biassoni R, Semino C, Casartelli G, Pasquetti W, Catrullo A, Moretta L. Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: functional and molecular characterisation for their use in adoptive immunotherapy. Eur J Cancer. 1994;30A:97–102. doi:10.1016/S0959-8049(05)80027-9.

Rizvi NA, Hellmann MD, Snyder A, Vose RH, Bivens CL, Kershaw MJ, et al. Landscape of immune checkpoint blockade in non-small-cell lung cancer. J Exp Med. 2017;214(20):4739–4753. doi:10.1084/jem.20170787.

Cui, F.; de Vries, K. G.; Arntzen, E. J. et al. Multiparametric profiling of non–small cell lung cancers reveals distinct immunophenotypes. JCI Insight. 2016;1:e90014. doi:10.1172/JCI.insight.89014.

Melioli G, Ratto GB, Ponte M, Guastella M, Semino C, Fantino G, Tassara E, Pasquetti W, Mereu C, Merlo F, et al. Treatment of stage IIIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Immunother Emphasis Tumor Immunol. 1996;19:224–230. doi:10.1002/2000-19906500-00007.

Melioli G, Ratto GB, Ponte M, Guastella M, Semino C, Fantino G, Tassara E, Pasquetti W, Mereu C, Merlo F, et al. Treatment of stage IIIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Immunother Emphasis Tumor Immunol. 1996;19:224–230. doi:10.1002/2000-19906500-00007.

Melioli G, Ratto GB, Ponte M, Guastella M, Semino C, Fantino G, Tassara E, Pasquetti W, Mereu C, Merlo F, et al. Treatment of stage IIIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Immunother Emphasis Tumor Immunol. 1996;19:224–230. doi:10.1002/2000-19906500-00007.

Melioli G, Ratto GB, Ponte M, Guastella M, Semino C, Fantino G, Tassara E, Pasquetti W, Mereu C, Merlo F, et al. Treatment of stage IIIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Immunother Emphasis Tumor Immunol. 1996;19:224–230. doi:10.1002/2000-19906500-00007.

Melioli G, Ratto GB, Ponte M, Guastella M, Semino C, Fantino G, Tassara E, Pasquetti W, Mereu C, Merlo F, et al. Treatment of stage IIIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Immunother Emphasis Tumor Immunol. 1996;19:224–230. doi:10.1002/2000-19906500-00007.

Melioli G, Ratto GB, Ponte M, Guastella M, Semino C, Fantino G, Tassara E, Pasquetti W, Mereu C, Merlo F, et al. Treatment of stage IIIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Immunother Emphasis Tumor Immunol. 1996;19:224–230. doi:10.1002/2000-19906500-00007.
34. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, Asher TE, Douek DC, Harari A, Pantaleo G, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses. J Exp Med. 2007;204:1405–1416. doi:10.1084/jem.20062363.

35. Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MAH, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MCW, et al. T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression. Ann Oncol. 2018;29:1575–1581. doi:10.1093/annonc/mdy087.

36. Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24:994–1004. doi:10.1038/s41591-018-0057-z.

37. Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL, Kaing S, Kelderman S, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 2018;174:1586–1598.e12. doi:10.1016/j.cell.2018.07.009.

38. Linnemann C, van Buuren MM, Bies L, Verdegaal EME, Schotte R, Calis JJA, Behjati S, Velds A, Hilkman H, El Atmioui D, et al. Corrigendum: high-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma. Nat Med. 2018;24:1192. doi:10.1038/nm.1016-1192d.

39. Tran E, Turcotte S, Gros A, Robbins PF, Lu Y-C, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344:641–645. doi:10.1126/science.1251102.

40. Veatch JR, Kwok WW, Riddell SR. Tumor-infiltrating BRAF V600E -specific CD4+ T cells correlated with complete clinical response in melanoma. J Clin Invest. 2018;128:1563–1568. doi:10.1172/JCI98689.

41. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, Boegel S, Schrös B, Vascotto F, Castle JC, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520:692–696. doi:10.1038/nature14426.

42. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207:637–650. doi:10.1084/jem.20091918.

43. Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpréville V, Validire P, Besse B, Mami-Chouaib F. CD8+ CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 2015;194:3475–3486. doi:10.4049/jimmunol.1402705.

44. Koh J, Kim S, Kim M-Y, Go H, Jeon YK, Chung DH. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma. Oncotarget. 2017;8:13762–13769. doi:10.18632/oncotarget.8188.

45. Muto S, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukahara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, et al. Clinical significance of expanded Foxp3+ Helios-regulatory T cells in patients with non-small cell lung cancer. Int J Oncol. 2015;47:2082–2090. doi:10.3892/ijo.2015.3196.

46. Ganesez A-P, Johansson M, Ruffell B, Beltran A, Lau J, Jablons DM, Coussens LM. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol. 2013;191:2009–2017. doi:10.4049/jimmunol.1301317.

47. Amsen D, van Gijsbergen KPJ, Hombrink P, van Lier RAW. Tissue-resident memory T cells at the center of immunity to solid tumors. Nat Immunol. 2018;19:538–546. doi:10.1038/s41590-018-0114-2.

48. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2015;5:200ra16. doi:10.1126/scitranslmed.3006504.